Journal of Biomolecular Screening
Share

Journal of Biomolecular Screening

2015 Impact Factor: 2.218
2015 Ranking: 73/161 in Biotechnology & Applied Microbiology | 44/77 in Biochemical Research Methods | 34/75 in Chemistry, Analytical
2016 Release of Journal Citation Reports, Source: 2015 Web of Science Data

Editor-in-Chief
Robert M. Campbell, PhD Eli Lilly & Company, Indianapolis, IN


eISSN: 1552454X | ISSN: 10870571 | Current volume: 21 | Current issue: 9 Frequency: 10 Times/Year


Advancing Life Sciences R&D! In January 2017, JBS will become SLAS Discovery.


JBS reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

The Journal of Biomolecular Screening (JBS) is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. JBS publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. JBS is an official journal of the Society for Laboratory Automation and Screening (SLAS).

The journal emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/ optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.

This publication will be of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.

This journal is a member of the Committee on Publication Ethics (COPE)

JBS reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.

The Journal of Biomolecular Screening (JBS) is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. JBS publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. JBS is an official journal of the Society for Laboratory Automation and Screening (SLAS).

The journal emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/ optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.

This publication will be of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.

This journal is a member of the Committee on Publication Ethics (COPE)

Editor-in-Chief
Robert M. Campbell, PhD Eli Lilly & Company, Indianapolis, IN
Associate Editors
Marc Bickle Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany
Steven Kahl Eli Lilly & Company, Indianapolis, IN
Ricardo Macarron GlaxoSmithKline - Collegeville, PA
Lorenz Mayr Novartis Pharma, Basel, Switzerland
Christian Parker Novartis Institutes for Biomedical Research, Basel, Switzerland
Reviews Editor
Peter Simpson N8 Research Partnership, Manchester, United Kingdom
Editorial Board
James Beasley Venenum Biodesign, Hamilton, NJ
Christine Brideau WuXi AppTec, Holmdel, NJ
Xianting Ding, PhD School of Biomedical Engineering, Shanghai Jiao Tong University, China
Hakim Djaballah Institut Pasteur Korea, Seongnam, South Korea
Juan Manuel Dominguez PharmaMar, Madrid, Spain
Frank Fan Promega, Madison, WI
Marc Ferrer NIH Chemical Genomics Center, Rockville, MD
Hanspeter Gubler Novartis Pharma, Basel, Switzerland
Charles Hart Threshold Pharmaceuticals, South San Francisco, CA
Rob Howes Medimmune, Cambridge, UK
Manfred Jung Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
Jose Julio Martin-Plaza GlaxoSmithKline, Tres Cantos, Spain
Larry Mattheakis Protagonist Therapeutics, Milpitas, CA
James McGee Eli Lilly & Company, Indianapolis, IN
Joseph McGivern Amgen Inc., Thousand Oaks, CA, USA
Robert Nadon, PhD Department of Human Genetics, McGill University, McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada
Andrew Pope GlaxoSmithKline - Collegeville, PA
Timothy Spicer The Scripps Research Institute, Jupiter, FL, USA
Masoud Vedadi University of Toronto, Canada
Francisca Vicente Fundación MEDINA, Granada, Spain
Mark Wade Center for Genomic Science of IIT@ SEMM, Milan, Italy
Ming-Wei Wang Chinese Academy of Sciences, Shanghai, China
Lixin Zhang Chinese Academy of Sciences, Beijing, China
Director of Publishing
Nan Hallock Society for Laboratory Automation and Screening - Manitowoc, WI
  • BIOSIS database
  • Biomolecular Interaction Network Database (BIND)
  • Biotechnology Citation Index®
  • Chemical Abstracts Service (CAS)
  • EMBASE/Excerpta Medica
  • EMBiology
  • Elsevier BV: BIOBASE
  • Index Medicus
  • InfoTrac (full text)
  • MEDLINE
  • Prous Science Integrity®
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • Thomson Reuters: BIOSIS Previews
  • Thomson Reuters: Current Contents - Life Sciences

  • Advancing Life Sciences R&D! In January 2017, JBS will become SLAS Discovery.

       English   Korean   Chinese (Simplified)   Chinese (Traditional)    Japanese
    Instructions for Authors    Korean Author Guidelines       Chinese Simplified    Chinese Traditional Japanese

    JBS SAGE Track (Submit a Manuscript)

    Average time from submission to first decision: 28 days

    Membership to the Society for Laboratory Automation and Screening includes a subscription to the Journal in both print and online access.

    Individual Subscription, Print Only


    Institutional Backfile Purchase, E-access (Content through 1998)


    Institutional Subscription, E-access


    Institutional Subscription, Print Only


    Institutional Subscription, Combined (Print & E-access)


    Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)


    Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)


    Individual, Single Print Issue


    Institutional, Single Print Issue